A phase I clinical trial using FAP-CAR-T-cells on patients with malignant pleural mesothelioma demonstrated that FAP-CAR-T-cell was well tolerated, and persistence of CAR T-cells was detected in the periphery (NCT01722149) (108). The gene discussed is FAP; the disease is malignant pleural mesothelioma.